Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis

New meta‐analyses are presented that provide further evidence supporting the effectiveness of oral prolonged‐release mesalazine compared to other oral mesalazines as induction therapy in patients with moderately active ulcerative colitis.[Image: see text]

Detalles Bibliográficos
Autores principales: Paridaens, Kristine, Fullarton, John R, Travis, Simon P L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366489/
https://www.ncbi.nlm.nih.gov/pubmed/37496812
http://dx.doi.org/10.1002/jgh3.12935
_version_ 1785077181143056384
author Paridaens, Kristine
Fullarton, John R
Travis, Simon P L
author_facet Paridaens, Kristine
Fullarton, John R
Travis, Simon P L
author_sort Paridaens, Kristine
collection PubMed
description New meta‐analyses are presented that provide further evidence supporting the effectiveness of oral prolonged‐release mesalazine compared to other oral mesalazines as induction therapy in patients with moderately active ulcerative colitis.[Image: see text]
format Online
Article
Text
id pubmed-10366489
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-103664892023-07-26 Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis Paridaens, Kristine Fullarton, John R Travis, Simon P L JGH Open Brief Report New meta‐analyses are presented that provide further evidence supporting the effectiveness of oral prolonged‐release mesalazine compared to other oral mesalazines as induction therapy in patients with moderately active ulcerative colitis.[Image: see text] Wiley Publishing Asia Pty Ltd 2023-07-07 /pmc/articles/PMC10366489/ /pubmed/37496812 http://dx.doi.org/10.1002/jgh3.12935 Text en © 2023 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Paridaens, Kristine
Fullarton, John R
Travis, Simon P L
Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
title Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
title_full Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
title_fullStr Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
title_full_unstemmed Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
title_short Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
title_sort efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366489/
https://www.ncbi.nlm.nih.gov/pubmed/37496812
http://dx.doi.org/10.1002/jgh3.12935
work_keys_str_mv AT paridaenskristine efficacyoforalprolongedreleasemesalazineinmoderatelyactiveulcerativecolitis
AT fullartonjohnr efficacyoforalprolongedreleasemesalazineinmoderatelyactiveulcerativecolitis
AT travissimonpl efficacyoforalprolongedreleasemesalazineinmoderatelyactiveulcerativecolitis

Ejemplares similares